Orbimed Capital Gp Viii Llc
Director at BlossomHill Therapeutics, Inc. (BLSM); Director at Sionna Therapeutics, Inc. (SION); 10% Owner at Traws Pharma, Inc. (TRAW)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 12SEC | BLSMBlossomHill Therapeutics, Inc. | Buy | 625,0002,714,279 held (+30%) | $16.00 | $10.0M | +9.3% |
| Jul 9SEC | SIONSionna Therapeutics, Inc. | Sell Plan | 85,9182,469,959 held (−3%) | $44.86 | $3.9M | -89.1% |
| Apr 28SEC | TRAWTraws Pharma, Inc. | Buy | 597,7291,203,250 held (+99%) | $1.67 | $998K | -73.1% |
| Feb 4SEC | SIONSionna Therapeutics, Inc. | Sell Plan | 1,8903,559,765 held (−0%) | $44.57 | $84K | -89.0% |
| Feb 4SEC | SIONSionna Therapeutics, Inc. | Sell Plan | 29,0633,530,702 held (−1%) | $44.58 | $1.3M | -89.0% |
| Dec 29SEC | SIONSionna Therapeutics, Inc. | Sell Plan | 33,3563,561,655 held (−1%) | $44.55 | $1.5M | -89.0% |
| Dec 19SEC | SIONSionna Therapeutics, Inc. | Sell Plan | 9003,595,986 held (−0%) | $44.50 | $40K | -89.0% |
| Dec 19SEC | SIONSionna Therapeutics, Inc. | Sell Plan | 1003,595,886 held (−0%) | $44.49 | $4K | -89.0% |
| Dec 19SEC | SIONSionna Therapeutics, Inc. | Sell Plan | 8753,595,011 held (−0%) | $44.49 | $39K | -89.0% |
- Buy
Director Orbimed Capital Gp Viii Llc bought $10.0M of BLSM at $16.00 — first open-market purchase in our records; raises the stake by 30%.
- Sell
Director Orbimed Capital Gp Viii Llc sold $3.9M of SION at $44.86 — pre-scheduled 10b5-1 plan sale.
- Buy
10% Owner Orbimed Capital Gp Viii Llc bought $998K of TRAW at $1.67 — first open-market purchase in our records; raises the stake by 99%.
- Sell
Director Orbimed Capital Gp Viii Llc sold $84K of SION at $44.57 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Orbimed Capital Gp Viii Llc sold $1.3M of SION at $44.58 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Orbimed Capital Gp Viii Llc sold $1.5M of SION at $44.55 — pre-scheduled 10b5-1 plan sale.